ATE306469T1 - Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine - Google Patents

Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine

Info

Publication number
ATE306469T1
ATE306469T1 AT00916444T AT00916444T ATE306469T1 AT E306469 T1 ATE306469 T1 AT E306469T1 AT 00916444 T AT00916444 T AT 00916444T AT 00916444 T AT00916444 T AT 00916444T AT E306469 T1 ATE306469 T1 AT E306469T1
Authority
AT
Austria
Prior art keywords
oxo
levels
dioxoisoindolines
substituted
lowering
Prior art date
Application number
AT00916444T
Other languages
English (en)
Inventor
George W Muller
David Stirling
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ATE306469T1 publication Critical patent/ATE306469T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT00916444T 1999-03-18 2000-03-17 Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine ATE306469T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12494299P 1999-03-18 1999-03-18
PCT/US2000/007029 WO2000055134A1 (en) 1999-03-18 2000-03-17 Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels

Publications (1)

Publication Number Publication Date
ATE306469T1 true ATE306469T1 (de) 2005-10-15

Family

ID=22417530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00916444T ATE306469T1 (de) 1999-03-18 2000-03-17 Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine

Country Status (22)

Country Link
US (1) US6380239B1 (de)
EP (1) EP1163219B1 (de)
JP (1) JP4728487B2 (de)
KR (1) KR100672892B1 (de)
CN (1) CN1342146A (de)
AT (1) ATE306469T1 (de)
AU (1) AU771015B2 (de)
BR (1) BR0010042A (de)
CA (1) CA2361806C (de)
CZ (1) CZ20013338A3 (de)
DE (1) DE60023123T2 (de)
DK (1) DK1163219T3 (de)
ES (1) ES2250121T3 (de)
FI (1) FI119881B (de)
HK (1) HK1042494A1 (de)
HU (1) HUP0200499A3 (de)
NO (2) NO320028B1 (de)
NZ (1) NZ513953A (de)
RU (1) RU2001121987A (de)
TR (1) TR200102688T2 (de)
TW (1) TWI229074B (de)
WO (1) WO2000055134A1 (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
ATE428419T1 (de) * 2001-08-06 2009-05-15 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
US7682803B2 (en) 2005-10-13 2010-03-23 Anthrogenesis Corporation Immunomodulation using placental stem cells
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
NZ570777A (en) * 2002-05-17 2009-04-30 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7354948B2 (en) 2002-11-06 2008-04-08 Celgene Corporation Methods for treatment of chronic uveitis using cyclopropyl-n-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN1738614A (zh) * 2002-11-18 2006-02-22 细胞基因公司 包含(－)－3－(3,4－二甲氧基－苯基)－3－(1－氧代－1,3－二氢－异吲哚－2－基)－丙酰胺的组合物及其使用方法
CH696542A5 (de) * 2003-07-09 2007-07-31 Siegfried Ltd Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
CA2545128C (en) * 2003-11-06 2010-01-12 Celgene Corporation Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CA2546493A1 (en) 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Indazole compounds and methods of use thereof as protein kinase inhibitors
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
BRPI0509019A (pt) * 2004-03-22 2007-08-07 Celgene Corp métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CA2562715A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
MXPA06012278A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
US7405237B2 (en) * 2004-07-28 2008-07-29 Celgene Corporation Isoindoline compounds and methods of their use
ES2438725T3 (es) * 2004-09-03 2014-01-20 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
AU2005302523A1 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
BRPI0518282A2 (pt) * 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
CA2612612C (en) * 2005-06-30 2014-03-11 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
AU2011221383B2 (en) * 2005-06-30 2013-08-01 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
AU2006265601A1 (en) * 2005-06-30 2007-01-11 Anthrogenesis Corporation Repair of tympanic membrane using placenta derived collagen biofabric
US20070021762A1 (en) * 2005-07-13 2007-01-25 Qing Liu Ocular plug formed from placenta derived collagen biofabric
EP1919500A2 (de) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Behandlung von beingeschwüren mit kollagen-biogewebe aus plazenta
US8715677B2 (en) 2005-09-01 2014-05-06 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
JP2009521931A (ja) * 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞を収集及び保存するための改善された組成物、及び該組成物の使用方法
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US8105634B2 (en) * 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US20080131522A1 (en) * 2006-10-03 2008-06-05 Qing Liu Use of placental biomaterial for ocular surgery
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
CA2665369C (en) 2006-10-06 2023-01-10 Anthrogenesis Corporation Human placental collagen compositions, and methods of making and using the same
RS52921B (sr) 2007-02-12 2014-02-28 Anthrogenesis Corporation Lečenje inflamatornih bolesti upotrebom placentnih matičnih ćelija
US10494607B2 (en) * 2007-02-12 2019-12-03 Celularity, Inc. CD34+,CD45−placental stem cell-enriched cell populations
WO2009020590A1 (en) 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
WO2009039635A1 (en) * 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
CA2700617C (en) 2007-09-28 2018-11-06 Celgene Cellular Therapeutics Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
CA2710196A1 (en) 2007-12-20 2009-07-09 Celgene Corporation Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
CA2756594C (en) 2009-03-25 2021-03-23 Anthrogenesis Corporation Treatment of viral infection using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
CN101580501B (zh) * 2009-06-01 2011-03-09 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
CA2786266A1 (en) 2010-01-05 2011-07-14 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
WO2012145309A1 (en) 2011-04-18 2012-10-26 Celgene Corporation Biomarkers for the treatment of multiple myeloma
EP2702410A2 (de) 2011-04-29 2014-03-05 Celgene Corporation Verfahren zur behandlung von krebs oder entzündungserkrankungen mit cereblon als prädiktor
KR20150029678A (ko) 2012-06-06 2015-03-18 바이오노르 이뮤노 에이에스 백신
MX358517B (es) 2012-06-29 2018-08-24 Celgene Corp Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
CN115137753A (zh) 2013-02-05 2022-10-04 细胞结构公司 来自胎盘的自然杀伤细胞
WO2014172429A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
CN103232380A (zh) * 2013-05-08 2013-08-07 中国药科大学 一种泊马度胺关键中间体的制备方法
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
EP3925609B1 (de) 2014-08-22 2025-07-30 Celgene Corporation Verfahren zur behandlung von multiplem myelom mit immunmodulatorischen verbindungen in kombination mit antikörpern
CN105440013B (zh) * 2014-08-29 2018-10-09 杭州和泽医药科技有限公司 一种泊马度胺的制备方法
WO2016210262A1 (en) 2015-06-26 2016-12-29 Celgene Corporation Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CN107365295B (zh) * 2016-05-11 2020-07-07 常州制药厂有限公司 一种泊马度胺合成工艺的改进方法
CN106432045B (zh) * 2016-06-29 2018-12-18 深圳海王医药科技研究院有限公司 一种泊马度胺杂质的合成方法
JP2019536460A (ja) 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｃａｒ−ｔ細胞の調節方法
US20200078404A1 (en) 2017-05-01 2020-03-12 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
EP3644721A1 (de) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mausmodell zur auswertung von toxizitäten im zusammenhang mit immunotherapien
US20200246393A1 (en) 2017-09-28 2020-08-06 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
WO2019164891A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
US12263190B2 (en) 2018-11-08 2025-04-01 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
CN113271963A (zh) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 给予工程化t细胞以治疗b细胞恶性肿瘤的方法
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP4543923A1 (de) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Behandlungsverfahren für die zweite therapie von cd19-gezielten car-t-zellen
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5855459A (ja) * 1981-09-26 1983-04-01 Dai Ichi Pure Chem Co Ltd 光学活性トリプトフアン誘導体の製造法
DE3366497D1 (en) * 1982-01-22 1986-11-06 Beecham Group Plc Antibacterial agents, their preparation and use
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
NL9300354A (nl) * 1993-02-25 1994-09-16 Futura Nova Bv Universeel toepasbare celverzamelinrichting.
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE69717831T3 (de) 1996-07-24 2018-08-30 Celgene Corp. Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE69734290T2 (de) 1996-11-05 2006-07-06 The Children's Medical Center Corp., Boston Mittel zur hemmung von angiogenese enthaltend thalodomid und einen nsaid
WO1998052919A1 (en) * 1997-05-21 1998-11-26 Japan Tobacco Inc. Phthalimide derivatives and pharmaceutical containing said derivatives

Also Published As

Publication number Publication date
FI119881B (fi) 2009-04-30
US6380239B1 (en) 2002-04-30
CA2361806C (en) 2012-03-13
DE60023123D1 (de) 2006-02-23
NO20054581L (no) 2001-11-16
AU771015B2 (en) 2004-03-11
TWI229074B (en) 2005-03-11
CZ20013338A3 (cs) 2002-03-13
FI20011839L (fi) 2001-09-18
HUP0200499A3 (en) 2002-12-28
HUP0200499A2 (en) 2002-06-29
ES2250121T3 (es) 2006-04-16
AU3755000A (en) 2000-10-04
NO320028B1 (no) 2005-10-10
DK1163219T3 (da) 2006-02-27
KR100672892B1 (ko) 2007-01-23
DE60023123T2 (de) 2006-06-22
RU2001121987A (ru) 2004-02-27
NO20013982D0 (no) 2001-08-16
HK1042494A1 (zh) 2002-08-16
BR0010042A (pt) 2002-01-15
JP4728487B2 (ja) 2011-07-20
WO2000055134A1 (en) 2000-09-21
KR20010109310A (ko) 2001-12-08
CN1342146A (zh) 2002-03-27
NZ513953A (en) 2001-09-28
JP2002539197A (ja) 2002-11-19
CA2361806A1 (en) 2000-09-21
NO20013982L (no) 2001-11-16
TR200102688T2 (tr) 2002-01-21
EP1163219A1 (de) 2001-12-19
EP1163219B1 (de) 2005-10-12

Similar Documents

Publication Publication Date Title
ATE306469T1 (de) Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
PT1064277E (pt) Derivados de 2-(2,6-dioxopiperidin-3-il)-isoindolinas, sua preparacao e sua utilizacao como inibidores de citocinas inflamatorias
SE9704404D0 (sv) New compounds
DE69816091D1 (de) Indol-derivate und ihre anwendung als mcp-1 antagonisten
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
NO983189L (no) Nye substituerte imidazolforbindelser
MY121136A (en) Novel heterocyclic sulfonamides.
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
ATE305787T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
NO20042861L (no) N-(3-butyn-1-yl)-N-hydroksyurea
MY119012A (en) New compounds
DE60103856D1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
ATE253059T1 (de) Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer
BG104396A (en) New carboxylic acid derivatives, carrying amido side-chains, production and use as endothelin receptor antagonists
BG103502A (en) Heterocyclic derivatives of carboxylic acids, their preparation and application as endothelial receptor antagonists
ATE382039T1 (de) Benzimidazolone und ihre verwendung als cytokininhibitoren
DK1537203T3 (da) ANVENDELSE AF DENDRITISKE CELLER (DC'er) DER UDTRYKKER INTERLEUKIN 12 (IL-12)
IL115791A (en) Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
DE59901563D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
DE69425823D1 (de) Substituierte chinolinderivate, und ihre verwendung als inhibitoren der magensekretion
DE69811962D1 (de) Substituierte 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindoline und ihre verwendung zur verminderung des tnfa spiegels
EA200200331A1 (ru) Применение лептина для ингибирования пролиферации эндотелиальных клеток
ATE19512T1 (de) 4-diphenylmethyl-1-((oxoalkyl)imino)methylpiperidine, und ihre derivate.
BG106154A (en) Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, methods for their production and their use as endothelin receptor antagonists
IT1294932B1 (it) Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1163219

Country of ref document: EP